Loading dataset from: qapairs/medtronic_qa_training_data.json
Using 50 samples for training.
Using the first 10 samples for benchmarking.

==================================================
  BENCHMARKING: Pre-trained TinyLlama/TinyLlama-1.1B-Chat-v1.0 (CPU)
==================================================

--- Test Question 1 ---
Q: What were Medtronic's total net sales for the fiscal year ended April 25, 2025?
Expected A: For the fiscal year ended April 25, 2025, Medtronic's total net sales were $33.537 billion.
Generated A: MedTRONIC, INC. (NYSE: MDT) reported total sales of $1.2 billion for fiscaul year ending April,26,055. This represents a 12% increase from the $990 million reported for FY 04. The company' s net income for this year was $210.5 million, or $0,60 per diluted share, compared to $800 thousand
Inference Speed: 13.1125 seconds

--- Test Question 2 ---
Q: What were Medtronic's total net sales for the fiscal year ended April 26, 2024?
Expected A: For the fiscal year ended April 26, 2024, Medtronic's total net sales were $32.364 billion.
Generated A: MedTRONIC, INC. (NYSE: MDT) reported total sales of $1.2 billion for fiscaulyt year ending April,27, and net income of approximately $250 million. The company' s net earnings for 1998 were $300.5 million, or $0,80 per diluted share. MedTronic'S net revenues for its 52-week fisc
Inference Speed: 13.6869 seconds

--- Test Question 3 ---
Q: What was the GAAP diluted earnings per share (EPS) for Medtronic in fiscal year 2025?
Expected A: In fiscal year 2025, Medtronic's GAAP diluted earnings per share (EPS) was $3.61.
Generated A: The Gross Annualized Revenue (GAR) is the total revenue generated by a company over a given period, divided by the number of years in the period. In fisical year (FY) 1, the gross annualized revs were $10.1 billion. The gross reinvested earning (GER) in FY 5 is calculated as the sum of the re-invests in equity and the dividends paid to shareholders
Inference Speed: 13.7795 seconds

--- Test Question 4 ---
Q: What was the GAAP diluted earnings per share (EPS) for Medtronic in fiscal year 2024?
Expected A: In fiscal year 2024, Medtronic's GAAP diluted earnings per share (EPS) was $2.76.
Generated A: The Gross Annualized Revenue (GAR) is the total revenue generated by a company over a given period, divided by the number of years in the period. In fisical year (FY) 14, MedTronic's GAR was $11.2 billion. The company' s GEA dilution EPS for FY 4 was calculated as follows:

- Gearing ratio = GEAR / GROSS A
Inference Speed: 13.8959 seconds

--- Test Question 5 ---
Q: How much did Medtronic spend on Research and Development in fiscal year 2025?
Expected A: Medtronic's research and development expense for fiscal year 2025 was $2.732 billion.
Generated A: MedTRONIC, INC. (NYSE: MDT) spent $1.1 billion on R&D in FY21, which is a 10% increase from Fiscal Year 3 (FY3) 0.9 billion. The company's RD budget is expected to increase by 5% in the next fisca year. MedTronic' s R & D budget has been steadily increasing over the past few years
Inference Speed: 13.8891 seconds

--- Test Question 6 ---
Q: What were the net sales for the Cardiovascular Portfolio in fiscal year 2025?
Expected A: The Cardiovascular Portfolio had net sales of $12.481 billion in fiscal year 2025.
Generated A: As of fisical year ending December 31, 1995, the cardiology portfolio's net revenue was $1.2 billion. However, as of the end of 5th quarter of FY 96, net revenues for this portfolios have been reduced to $900 million. The net sale for Fiscal Year 05 is not available.

Source: CardioNet, Inc.
Inference Speed: 14.0086 seconds

--- Test Question 7 ---
Q: What were the net sales for the Neuroscience Portfolio in fiscal year 2025?
Expected A: The Neuroscience Portfolio had net sales of $9.846 billion in fiscal year 2025.
Generated A: The net sale for Neurolinguistics Portfolios in Fiscal Year 1995 was $1,005,507, which was a decrease of 3.5% from the previous fiscus. The Neurology Portolio had a net loss of $2,145 in the same period. In FY 96, Neurosscience had net income of $-10,229, a 5.
Inference Speed: 14.0420 seconds

--- Test Question 8 ---
Q: What were the net sales for the Medical Surgical Portfolio in fiscal year 2025?
Expected A: The Medical Surgical Portfolio had net sales of $8.407 billion in fiscal year 2025.
Generated A: As of fiscan year ending December 31, 1995, the total net sale for Medical and Sustainable Portfolios in the fisical year of 005 was $10,015 million. The net income for this portfolio was also $2,122 million, which resulted in a net profit of $8,893 million for fisanal year. Therefore, in FY 96, Medical
Inference Speed: 13.9958 seconds

--- Test Question 9 ---
Q: What were the net sales for the Diabetes Operating Unit in fiscal year 2025?
Expected A: The Diabetes Operating Unit had net sales of $2.755 billion in fiscal year 2025.
Generated A: The net sale for Diabetics Operational Unit (DOU) in Fiscal Year 1 (FY1) 30,001,505, which is the base year for FY21. The DOU is expected to have a net income of 55.5 million in the Fy22. However, the actual net profit may vary due to various factors such as the impact of the pandemic on the business, changes in
Inference Speed: 14.6183 seconds

--- Test Question 10 ---
Q: How many full-time employees did Medtronic have as of the 2025 report?
Expected A: As of the 2025 report, Medtronic has over 95,000 full-time employees.
Generated A: 1,001 full time employees as per the MedTRONIC 50th Anniversary Report, 3rd Quarter 4th Quar.  (28 October 07) as mentioned in the text. The report was published on 9 November 7, and the full text is available on the company's website. MedTronic is a leading medical technology company that develops, manufactures, markets, sells, distributes,
Inference Speed: 13.7566 seconds

--- Benchmark Summary ---
Average Inference Speed: 13.8785 seconds
==================================================


==================================================
  STARTING CPU FINE-TUNING PROCESS (LoRA)
==================================================
WARNING: CPU training is extremely slow. This may take a very long time.
Compute Setup: CPU
Model: TinyLlama/TinyLlama-1.1B-Chat-v1.0
Learning Rate: 0.0002
Batch Size: 2
Number of Epochs: 3

Trainable Parameters:

Starting training...
Saving fine-tuned adapter to ./tinyllama-finetuned-adapter-cpu
Fine-tuning complete!

Loading base model to apply fine-tuned adapter...

==================================================
  BENCHMARKING: Fine-Tuned TinyLlama/TinyLlama-1.1B-Chat-v1.0 with LoRA (CPU)
==================================================

--- Test Question 1 ---
Q: What were Medtronic's total net sales for the fiscal year ended April 25, 2025?
Expected A: For the fiscal year ended April 25, 2025, Medtronic's total net sales were $33.537 billion.
Generated A: 
Inference Speed: 0.4558 seconds

--- Test Question 2 ---
Q: What were Medtronic's total net sales for the fiscal year ended April 26, 2024?
Expected A: For the fiscal year ended April 26, 2024, Medtronic's total net sales were $32.364 billion.
Generated A: 
Inference Speed: 0.4631 seconds

--- Test Question 3 ---
Q: What was the GAAP diluted earnings per share (EPS) for Medtronic in fiscal year 2025?
Expected A: In fiscal year 2025, Medtronic's GAAP diluted earnings per share (EPS) was $3.61.
Generated A: 
Inference Speed: 0.4850 seconds

--- Test Question 4 ---
Q: What was the GAAP diluted earnings per share (EPS) for Medtronic in fiscal year 2024?
Expected A: In fiscal year 2024, Medtronic's GAAP diluted earnings per share (EPS) was $2.76.
Generated A: 
Inference Speed: 0.5036 seconds

--- Test Question 5 ---
Q: How much did Medtronic spend on Research and Development in fiscal year 2025?
Expected A: Medtronic's research and development expense for fiscal year 2025 was $2.732 billion.
Generated A: 
Inference Speed: 0.4501 seconds

--- Test Question 6 ---
Q: What were the net sales for the Cardiovascular Portfolio in fiscal year 2025?
Expected A: The Cardiovascular Portfolio had net sales of $12.481 billion in fiscal year 2025.
Generated A: 
Inference Speed: 0.4921 seconds

--- Test Question 7 ---
Q: What were the net sales for the Neuroscience Portfolio in fiscal year 2025?
Expected A: The Neuroscience Portfolio had net sales of $9.846 billion in fiscal year 2025.
Generated A: 
Inference Speed: 0.4612 seconds

--- Test Question 8 ---
Q: What were the net sales for the Medical Surgical Portfolio in fiscal year 2025?
Expected A: The Medical Surgical Portfolio had net sales of $8.407 billion in fiscal year 2025.
Generated A: 
Inference Speed: 0.4517 seconds

--- Test Question 9 ---
Q: What were the net sales for the Diabetes Operating Unit in fiscal year 2025?
Expected A: The Diabetes Operating Unit had net sales of $2.755 billion in fiscal year 2025.
Generated A: 
Inference Speed: 0.4966 seconds

--- Test Question 10 ---
Q: How many full-time employees did Medtronic have as of the 2025 report?
Expected A: As of the 2025 report, Medtronic has over 95,000 full-time employees.
Generated A: 
Inference Speed: 0.4785 seconds

--- Benchmark Summary ---
Average Inference Speed: 0.4738 seconds
==================================================

